The ways of erlotinib resistance overcoming in treatment of patients with eGFr mutated nsClC
The aspects of chemotherapy and erlotinib combination to treatment of non-small-cell lung cancer (NSCLC) are examined in the article. Mechanisms of ITK resistance acquiring and potential ways to its overcoming are discussed. In the randomized clinical trial FASTACT-II the intercalated combination of...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2013-12-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/26916 |